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Upon immunization, a variety of events occur in lymphatic tissue. One of the 
earliest is the trapping of recirculating lymphocytes within the draining lym- 
phatic organs (1). The trap may promote interaction of antigen, macrophages, 
and specific immunocompetent cells. 
Frost and Lance reported that cell-free ascitic fluid (AF)' inhibits lymphocyte 
trapping (2). We confirmed this with fluid from other ascites tumors (3). In this 
report we show that lactic dehydrogenase virus (LDV), a common passenger in 
many mouse tumors (4, 5), is a trapping inhibitory component in the tumor AFs. 
After injection of LDV, the virus replicates quickly and reaches a peak titer in 
24 h. It causes a permanent viremia with the most obvious manifestation being 
an  elevation in plasma  lactic dehydrogenase (LDH)  (4). The virus probably 
replicates exclusively in macrophages (6). It affects reticuloendothelial system 
(RES) function (7), causes histological changes in lymphatic tissue (6), and alters 
some immune responses (8, 9). We have studied the effect of LDV on lymphocyte 
circulation and have attempted to analyze the mechanism of LDV inhibition of 
the lymphocyte trap. 
Materials and Methods 
Animals.  Female BALB/c mice, 2-4 mo of age, and female Swiss Webster rats were obtained 
from Simonsen Farms (Gilroy, Calif.). Specific pathogen-free (SPF) female BALB/c, 3-6 mo of age, 
were obtained from Dr. R.  Kallman (Department of Radiology, Stanford University). 
Ascites Tumors.  L4946, Ascitic lymphoma, and Krebs-2 tumors were all cultivated in BALB/c 
mice in the ascitic form. Their derivations are as previously reported (3). The Ehrlich ascitic tumor 
was kindly donated by Dr. Howard Fieldsteihl of Stanford Research Institute. Cell-free AF was 
prepared by centrifugation at 1,000 g  for 20 min at 5°C. 
* This project was supported by Research Grant No. AI09341 and Training Grant No. AI00082 
awarded by the National Institute of Allergy and Infectious Diseases, DHEW. 
Abbreviations used in this paper:  AF,  ascitic fluid; Con A, concanavalin A; FCS,  fetal calf 
serum:  LDH,  lactic dehydrogenase; LDV,  lactic dehydrogenase virus; LN,  lymph node; NMS, 
normal  mouse  serum;  PBS,  phosphate-buffered  saline;  PHA-P,  phytohemagglutinin P;  RES, 
reticuloendothelial system; SPF, specific pathogen-free; SRBC,  sheep red blood cells. 
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LDV Cultivation  and Assay.  LDV (supplied by Spencer Hiraki) was cultivated in SPF BALB/c 
mice. LDH levels, indicative of LDV infection, were assayed by the method of Riley (10). 
Cell Suspensions.  Cell suspensions were prepared from pooled axillary,  brachial, inguinal, 
and mesenteric lymph nodes of donor mice, and cells were labeled with sodium chromate (51Cr) by 
procedures previously described (3). 
Lymphocy~ Trapping Assay.  Trapping was measured by the method of Zatz and Lance (1). 
Trapping was elicited by a  dose of 6  ×  l0  s sheep red blood cells (SRBC) injected subcutaneously 
(s.c.) on the anterior and posterior right flanks. The distribution of 107 intravenously (i.v.) injected 
slCr-labeled syngeneic lymphocytes in recipient mice was then determined. 
24 h  subsequent to labeled lymph node (LN) cell injection brachial, axillary, and inguinal LNs 
were removed and pooled,  preserving bilateral symmetry.  The radioactivity within the pooled 
antigen-draining and the pooled contralateral (control) LNs was measured.  The recovery in the 
pooled antigen-draining LNs of each mouse was expressed as a percentage of the recovery in the 
pooled control LNs utilizing the standardization procedure described previously (3). 
Ether Fractionation  ofEhrlich AF.  The ether inactivation method of Notkins (11), involving 
three ether extractions, was used to inactivate LDV. A sham-fractionated preparation was shaken 
without ether. 
Ultraviolet (UV) Inactivation of  LDV.  LDV-infected AF was sonicated for 30 s to disaggregate 
the virus particles. A 60-mm petri dish containing 2 ml of a  1:10 dilution of sonicated Ehrlich cell- 
free AF in 0.15 M  NaC1 was placed under a  (General Electric Co.,  Cleveland, Ohio) germicidal 
lamp and received 6,575 ergs/cm  2 per s. The AF was mechanically agitated during exposure. From 
an inactivation curve, 4 min was the minimal dose selected for complete inactivation of LDV. The 
treated preparation, in a dose initially equal to l0  T  LDV infectious units, was assayed for LDV and 
for its ability to inhibit lymphocyte trapping. A sham UV inactivated preparation was also assayed. 
Passage of  Ehrlich Ascites Tumor in Irradiated Rats.  Ehrlich ascites tumor was freed of LDV 
by passage in animals that do not support LDV replication (10). Swiss Webster rats were lethally 
irradiated with 900 R, and 2 h  later were injected i.p. with 2.4  ×  107 Ehrlich tumor cells.  7 days 
later, the ascites cells were harvested and passaged into SPF BALB/c mice. AF was collected after 
the first and second BALB/c tumor passage after rat passage and tested for LDV and trapping 
inhibitory capacity. 
In Vitro Incubation of Lymph Node Cells with LDV-lnfected L4946 AF. 51Cr-labeled LN cells 
(1.5  ×  los)  were  incubated in  (a)  medium  199  +  15%  fetal calf serum  (FCS)  +  30%  0.22  ~m 
millipere-filtered IA946 AF containing 5 ×  l0  s LDV or (b) medium 199 +  15% FCS with occasional 
shaking in a  37°C water bath. After 30-min incubation, the cells were centrifuged, washed twice, 
and resuspended for injection. Viabilities of both groups of cells were determined by trypan blue 
dye exclusion. 
Mitogen Stimulation of Lymphocytes  in Cultures  Containing Cell-Free Ehrlich Ascitic Fluid or 
Normal Mouse Serum (NMS). Mitogens used for stimulation were Concanavalin A (Con A) (Phar- 
macia Fine Chemicals,  Uppsala,  Sweden) and Phytohemagglutinin P  (PHA-P) (Difco Laborato- 
ries, Detroit, Mich.). In the different test media used, the optimum Con A and PHA-P concentra- 
tions for stimulation were always 1 ~g and 4  ×  10  -4 ml stock per culture, respectively. Cells used 
were: (a) unfractionated LN cells containing 60% Ig negative cells or (b) LN cells enriched for T 
cells by nylon wool fractionation (12) and containing 90% Ig negative cells. In addition to 5  ×  los 
cells,  at 0  h  each well in a  sterile,  flat-bottomed microculture plate (Falcon Plastics,  Oxnard, 
Calif.)  contained either  Con  A,  PHA-P,  or  medium  (RPMI-1640  +  4%  FCS)  and  either  10% 
millipore-filtered Ehrlich AF (containing 107 LDV/culture) or 5% NMS (protein concentration in 
NMS is twice that of the ascitic fluid). The total culture volume was 0.2 ml. After 48-h incubation 
at  37°C  in a  humidified,  5%  CO2  atmosphere,  1.0 /~Ci  [3H]thymidine (New  England  Nuclear, 
Boston,  Mass.)  was  added  to  each culture.  Cultures  were harvested at  72  h  on a  MASH  unit 
(multiple automatic sample  harvester).  The cell-incorporated radioactivity remaining on glass 
filter disks was measured. 
Statistics.  Results are expressed as means within each group ±  SE. The probability (P) values 
were determined by Student's t test. 
Results 
Lymphocyte Trapping and Its Inhibition by Cell-Free Tumor AF.  Groups of 
mice were injected  s.c.  in the  right flanks  with  SRBC  or phosphate-buffered 102  INHIBITION  OF  LYMPHOCYTE  TRAPPING  BY  LDV 
TABLE  I 
Recovery of 51Cr-LN Cells and Percent Trapping in LNs of Mice Injected with 
Antigen or PBS 
Recovery as percent of injected dose  ±  SE 
SRBC (n = 52)  PBS (n = 23) 
Pooled right LNs  4.59 ±  0.16  2.40 ±  0.17 
Pooled left LNs  2.00 ±  0.08  2.22  ±  0.16 
P  value*  P  <  0.001  P  >  0.2 
Percent trappings  130  ±  6  8  ±  4 
Mice received 6  x  10  s SRBC or 0.2 ml PBS s.c. on the right flanks 24 h  before i.v. 
injection of 107 51Cr-LN  cells. 24 h  after labeled cell infusion, mice were sacrificed, 
radioactivity in LNs measured, and percent trapping calculated. 
* Probability that recovery in pooled right LNs differs significantly from recovery in 
pooled left LNs. 
In this experiment percent trapping was calculated by the following formula: 
%trapping=  (recoveryinantigen-drainingLNs  x  100)-100. 
recovery in contralateral LNs 
saline, (0.1 M, pH 7.2).  24 h  later 107 51Cr-labeled  LN cells were injected i.v. 
Antigen-draining and contralateral LNs were excised after 24 h and the radioac- 
tivity in the nodes determined. The data in Table  I  show that a  significant 
increase in lymphocyte localization occurred in the peripheral LNs draining the 
site of antigen injection. This increase is designated lymphocyte trapping. 
To demonstrate inhibition of trapping by tumor AF,  groups of mice were 
injected with antigen alone,  antigen and cell-free tumor AF, or antigen and 
NMS. The mice treated with AF received three 0.5 ml doses of AF 72, 48, and 24 
h  before labeled cell infusion. The same schedule was used to treat mice with 
three 0.25-ml  doses of syngeneic mouse serum.  A  dose of 0.25  ml  NMS  was 
approximately equal in protein concentration to 0.5  ml AF. All mice received 
SRBC s.c. on the right flanks 24 h before the labeled cells, and the protocol for 
assaying trapping  was  followed.  Fig.  1  shows  the  significant inhibition of 
trapping observed in mice infused with cell-free AF from four murine tumors: 
L4946, Ehrlich, Ascitic Lymphoma, and Krebs-2. NMS had no inhibitory effect. 
These results agree with our previously published results in C3H-Bi mice (3). 
AF passed through 0.22 izm millipore filters also inhibited trapping (data not 
given). 
Presence of LDV in Cell-Free Tumor AF.  Groups of SPF BALB/c mice were 
injected i.p. with 0.3 ml of  cell-free tumor AF or NMS. 4 days later the mice were 
tested for increases in LDH levels indicative of LDV infection. The range of  LDH 
levels in plasma of normal mice was 180-1,110  LDH U/ml with a  mean of 449 
LDH U/ml. Mice injected with fluid from IA946,  Krebs-2, Ascitic Lymphoma, 
and Ehrlich tumors showed an approximately eightfold increase in LDH levels. 
Mice injected with NMS exhibited normal LDH levels. Thus, each fluid that 
inhibited trapping was found to contain LDV. PATRICIA  K.  A.  MONGINI  AND  LEON  T.  ROSENBERG  103 
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Inhibition of lymphocyte trapping by cell-free tumor ascitic fluid. Before labeled 
cells,  all  mice  received  SRBC s.c.,  and  some  received  i.v.  infusions  of  various  cell-free  tumor 
ascitic  fluids  or NMS. Each bar represents the mean of 4-8 mice -+ SE. The P  values 
indicate  the probability  that the percent trapping in i.v.  treated  mice is not significantly 
different  from that in control,  untreated mice. 
Dose  Response  of  Trapping  Inhibition  and  LD V  Infection  by 
AF.  Concurrently with the trapping eliciting dose of SRBC,  groups of mice 
were injected i.v. with dilutions of cell-free Ehrlich AF in medium 199 or with 
medium alone. Plasma LDH levels and trapping were assayed as described. 
Fig.  2  illustrates  the  dose  response  of LDV  infectivity and  inhibition of 
trapping by Ehrlich AF. The group of mice that received 50-5  ×  10 -7 ml of AF 
exhibited a significant (P <  0.001) inhibition of trapping as well as a significant 
(P  <  0.001) rise in plasma LDH levels indicative of LDV infection. 6 of the 10 
mice that received 5 ×  10  -s ml of AF exhibited significantly (P <  0.002) elevated 
levels of LDH. With only one exception, the mice that exhibited elevated LDH 
levels were inhibited from trapping, while the mice with normal LDH levels had 
normal trapping levels. Thus the minimum dose of AF required for trapping 
inhibition correlates with the minimum dose of AF required to elevate LDH 
levels in recipient mice. 
Effect of Procedures  that Eliminate  LDV  Upon the  Trapping  Inhibitory 
Capacity of Tumor AF.  To clarify if LDV was the inhibitory component in 
tumor  AF,  ether  fractionation  and  UV  irradiation  of infected  AF  and  rat 
passage  of the  infected tumor were  used  to  eliminate infectious LDV.  SPF 
BALB/c mice which received a trapping eliciting dose of SRBC simultaneously 
received 0.3  ml  of ether-  or  sham-fractionated Ehrlich AF  or  UV-  or  sham- 
irradiated Ehrlich AF i.v. Other groups of mice received three doses of  0.5 ml AF 
from rat-passaged or nonrat-passaged Ehrlich tumor i.v. at 48, 24, and 0 h before 
s.c. SRBC injection. Trapping was assayed and LDH levels measured. 104  INHIBITION  OF  LYMPHOCYTE  TRAPPING  BY  LDV 
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FIG.  2.  Dose  response  of  trapping  inhibition  and LDV infection  with  cell-free  Ehrlich 
ascitic  fluid.  The  percent  trapping  (bars)  - SE and  the  LDH enzyme  levels  (0) _+  SE are 
plotted  as  a  function  of  the  dose  of  ascitic  fluid  injected. 
As shown in Fig. 3 A mice injected  with ether-treated  AF exhibited as much 
trapping as control  mice that received no AF. Trapping in mice that received 
sham-fractionated AF  was depressed. Ether-treated  AF  no longer had the 
capacity to elevate  plasma LDH  levels  in recipient  mice. 
The  effect  of  UV-irradiated  AF upon  lymphocyte  trapping  is  illustrated  in  Fig. 
3 B. Only 1 of  the 13 mice that received UV-treated AF exhibited significant 
inhibition  of trapping. This mouse had an elevated plasma LDH  level  (3,270 
LDH  U/ml) indicative  of  LDH  infection.  Mice that  received  sham-irradiated  AF 
were infected  with LDV  and were significantly  inhibited  from trapping. Thus, 
UV irradiation  abolished the  trapping  inhibitory  capacity  of  tumor AF, and  this 
appeared to be dependent upon the inactivation  of  LDV. 
As shown in Fig. 3 C the percent  trapping  in mice treated with rat-passaged 
Ehrlich  tumor  AF was  not  significantly  different  from  that  in  mice  that  received PATRICIA K.  A.  MONGINI AND  LEON T.  ROSENBERG  105 
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FIG. 3.  Test of the trapping  inhibitory  capacity of tumor AF after various treatments to 
eliminate infectious LDV. (A) Effect of ether-treated  tumor AF upon lymphocyte trapping. 
Percent trapping (bars) and plasma LDH levels (e) were assayed in mice that received only 
SRBC s.c. or SRBC and i.v. infusion of ether-treated  or sham-treated AF. (B) Effect of UV- 
irradiated  AF upon trapping.  Mice received only SRBC s.c. or SRBC s.c. and UV-irradiated 
or sham-irradiated  AF i.v. The AF dose contained 107 infectious units before UV treatment. 
(C) Effect of AF from a rat-passaged tumor upon trapping.  Mice received only SRBC s.c. or 
SRBC s.c. and AF from rat-passaged or nonrat-passaged Ehrlich ascitic tumor i.v. 
no AF.  Mice  treated  with  AF from the  same  tumor before  rat  passage  were 
inhibited in trapping. 
To recapitulate,  the elimination of infectious  LDV by dilution,  ether-treat- 
ment,  UV  irradiation,  and  rat  passage  of the  infected  tumor  abolished  the 
trapping  inhibitory capacity of tumor AF.  LDV appears  to  be  the  inhibitory 
component in our tumor AFs.  Experiments performed with LDV in plasma of 
nontumor-bearing  mice  indicated  that  LDV,  dissociated  from  tumors,  could 
inhibit trapping (see Fig. 4). 
Effect  of  Time  of  LDV  Administration  Upon Inhibition  of  Trap- 
ping.  Trapping  occurs  soon  after  antigen  reaches  the  draining  lymphatic 
tissue.  Within  15  min  after i.v.  injection  and within  24  h  after  s.c.  injection, 
trapping can be measured in the spleen and lymph node, respectively (1,  13). To 
determine if LDV could inhibit a trapping response already initiated, groups of 
mice were injected i.v. with 10  e LDV 0, 6, 12, 24, 36, 40, or 45 h after s.c. injection 
with SRBC. Trapping was assayed. Fig. 4 shows the increases in trapping seen 
when LDV is given at increasing time  intervals  after SRBC injection.  When 
LDV was injected up to 12 h after SRBC only 40% trapping was observed. IfLDV 106  INHIBITION  OF  LYMPHOCYTE  TRAPPING  BY  LDV 
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FIc.  4.  Effect of time of LDV administration upon inhibition of trapping. The amount of 
trapping in LNs of mice that received SRBC s.c. is plotted as a function of time of i.v. 
infusion with 107 LDV in plasma of nontumor-bearing  mice. The percent trapping in mice 
that received no LDV is also shown (©). 
was not given until 24 h  after SRBC 73% trapping was observed. Mice receiving 
LDV 36-45 h  after antigen had comparable levels of trapping as control mice. 
Thus  LDV  was  not as  efficient in  inhibiting  trapping  when  given late  after 
antigen injection. This suggests that to inhibit trapping LDV must be present 
before trapping is initiated and/or some replication of the virus must occur. 
Trapping  Inhibition  in  Mice  Acutely  or  Chronically  Infected  with 
LDV.  Mice acutely infected with LDV exhibit elevated plasma LDH levels (8), 
impaired  RES carbon clearance (7),  and  a  depletion of lymphocytes in the T- 
cell  dependent  areas  of lymphatic  tissues  (6).  Except for  the  elevated  LDH 
levels, these effects are transient (6-8).  To determine if the inhibition of trap- 
ping occurs in only the acute or in both acute and chronic infections, SRBC were 
injected s.c. into mice that had received 106 LDV i.v. 9 days previously (chronic 
LDV infection) or that were to receive 10  ~ LDV i.v. concurrently with antigen 
(acute LDV infection). Trapping was assayed.  Mice (n  =  52) not infected with 
LDV exhibited 130_+6% trapping, while mice (n =  13) acutely infected exhibited PATRICIA  K.  A.  MONGINI  AND  LEON  T.  ROSENBERG  107 
TABLE  II 
Effect of Infusion of LD  V-Infected Tumor Ascitic Fluid, LDV-Infected Plasma, or 
NMS upon Lymphocyte Localization in Nonantigen Draining LNs 
i.v. treatment*  n  Recovery -+ SE  P  values 
% 
None  77  2.12  _+ 0.06  -- 
LDV-infected Krebs-2 AF  6  3.08 _  0.24  <0.001 
LDV-infected L4946 AF  12  3.03  -+ 0.16  <0.01 
LDV-infected Ehrlich AF  32  3.18 -+ 0.08  <0.001 
LDV-infected plasma (day -1)  10  3.39  -- 0.20  <0.001 
LDV-infected plasma (day -10)  3  2.46  _+ 0.34  :>0.2 
Ether-treated Ehrlich AF  2  1.90 _+ 0.08  >0.5 
Rat-passaged Ehrlich AF  18  1.60 -+ 0.07  <0.001 
LDV-free L4946 AF  6  2.60 _+ 0.29  >0.1 
NMS  4  1.74  -+ 0.16  >0.1 
* Mice received doses of 3 x  0.5 ml LDV-infected Krebs-2 or L4946 AF, 3  x  0.5 ml or I  × 0.5 
ml LDV-infected Ehrlich AF, 0.1 ml LDV°infected plasma, 0.3 ml ether-treated AF, 3  × 
0.5 ml rat°passaged tumor AF, 3  x  0.5 ml LDV-free L4946 AF, or 3  x  0.25 mi NMS at 72, 
48, and 24 h  before or at 24 h  before labeled LN cells. One group of mice received LDV- 
infected plasma 10 days before labeled LN cells. 24 h after labeled cell injection, LNs were 
excised, and the recovery of cells in pooled unilateral LNs was measured. 
S Probability that recovery of labeled cells in treated mice is not significantly different from 
recovery in control untreated mice. 
36-_-6% trapping,  a  significantly  (P  <  0.001)  lesser  amount.  No inhibition  of 
trapping  was observed in mice (n  =  3) chronically infected with LDV.  These 
mice  exhibited  117___9% trapping.  Both  acutely and  chronically  infected mice 
exhibited levels of LDH significantly above control levels. 
Effect of Infusion  of Cell-Free  Tumor AF, LDV-Infected Plasma, or NMS 
Upon Lymphocyte Localization  in Nonantigen-Draining  LNs.  In our assays 
for lymphocyte trapping  we observed that mice receiving LDV-infected fluids, 
but not SRBC, exhibited an increased labeled cell localization in LNs compared 
to mice not receiving LDV. The observations are presented here. The recovery of 
labeled lymphocytes in LNs of mice that had received an i.v. injection of LDV- 
infected tumor AF, LDV-infected plasma,  LDV-free tumor AF,  or NMS before 
labeled  cell  infusion  was  compared  to  the  recovery of lymphocytes  in  mice 
receiving no i.v. treatment.  The recovery in LNs of mice that had received i.v. 
injection of LDV-infected plasma 10 days previous to labeled cell injection was 
also compared to the recovery in LNs of mice that received no i.v. treatment. 
The assayed LNs did not drain the site of SRBC injection. 
The results demonstrate (Table II) that a  very significant increase in labeled 
cell recovery occurs in the unilaterally pooled inguinal,  axillary,  and brachial 
LNs of mice receiving LDV-infected Krebs-2, L4946, and Ehrlich  cell-free AFs 
and in mice receiving LDV-infected plasma shortly before injection of labeled 
lymphocytes. The cell localization in mice that received virus-infected plasma 10 
days before labeled cells, however, was not altered. LDV-free AFs did not cause 
any increase in lymphocyte localization in peripheral nodes. The cell recovery in 
mice  infused  with  rat-passaged  Ehrlich  AF was,  however,  significantly  less 
than the recovery in control mice. 108  INHIBITION  OF  LYMPHOCYTE  TRAPPING  BY  LDV 
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Effect  of in  vitro  incubation  with  LDV-infected  AF  upon  the  ability  of donor 
lymphocytes to  be  trapped.  (A)  Labeled  cells were  incubated  in  vitro  with  30%  cell-free 
Ehrlich AF or with medium alone before i.v. transfer into mice that had received SRBC s.c. 
Trapping  in  the  SRBC-draining  nodes  was  subsequently  measured.  (B)  Trapping  was 
assayed in mice treated as described in Fig.  1. 
Effect of Increasing Labeled Lymphocyte Dose Upon Labeled Cell Recovery in 
Antigen-Draining  LNs.  Inasmuch as  infusion with  LDV-infected fluids re- 
suited in increased retention of labeled cells in peripheral LNs, we tested to see 
if the  inhibition of SRBC-induced trapping  was  due  to  a  saturation of the 
antigen-draining LNs with lymphocytes. Increasing numbers of labeled lympho- 
cytes were injected i.v. into mice that 24 h  previously had received a  trapping 
eliciting dose of SRBC together with an i.v. injection of 0.3  ml cell-free LDV- 
infected Ehrlich AF.  When los,  107, or l0  s labeled lymphocytes were injected, 
2.01  x  104, 2.03  ×  105, and 1.37  x  los cells, respectively, were recovered in the 
antigen-draining LNs. Since the cell recovery is nearly linear, we conclude that 
the inhibition of SRBC-elicited trapping is not due to LN saturation produced by 
the increased lymphocyte localization in LNs after LDV treatment• 
Effects of In Vitro Incubation of Labeled Donor Cells with LD V-Infected Cell- 
Free Ascitic Fluid.  LDV may affect circulating cells so as to make them less 
able to be trapped. To test this possibility, labeled LN cells were incubated with 
30% LDV-infected Ehrlich AF or with medium alone for 30 min at 37°C. Cells 
were washed twice, their viability shown to be unaffected  by treatment with AF, 
and injected i.v. into mice that had 24 h previously received SRBC s.c. As shown 
in Fig. 5 the amount of trapping that occurred when labeled donor LN cells were 
incubated with LDV-infected tumor AF was not significantly different  from that 
in mice infused with cells incubated in medium alone. This is in contrast to the 
very significant inhibition of trapping observed when the AF was administered 
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TABLE  III 
Mitogen Stimulation of Lymphocytes  with LDV-Infected  AF or NMS in the Culture Medium 
Culture medium additive 
Mean cpm x  10'/culture ±  SE 
Con A  PHA-P 
LN Cells  T-cell enriched LN  LN cells  T-cell enriched 
cells  LN cells 
10% Ehrlich AF,  14.15 ±  2.55 (6)*  8.13 ±  4.21 (3)  3.73  ±  1.18 (6)  3.35 ±  1.88 (3) 
(107 LDV/culture) 
5% NMS$  14.77 ±  1.24 (6)  11.82 ±  2.78 (3)  2.01 ±  0.41 (6)  3.31  -+  1.34 (3) 
P  value§  >0.5  >0.2  >0.1  >0.5 
Unstimulated cultures contained approximately 125 cpm. 
* Number of experiments with 3 or 6 replicates/experiment. 
~t Medium with 5% NMS had an equivalent protein concentration to medium with 10% Ehrlich AF. 
§ Probability that stimulation in cultures containing LDV-infected AF is not significantly different from cultures 
containing NMS. 
cells  with  AF  is  probably  due  to  transfer  of some virus  with  the  cells  at  a 
considerable time after injection of antigen that elicited trapping. 
Mitogen Stimulation of L ymphocytes with LD V-Infected Cell-Free Tumor AF 
or NMS  in  the Culture  Medium.  LDV may inhibit  trapping  by preventing 
induction  of the trap.  Macrophages and T  cells have each been implicated in 
inducing  the  lymphocyte trap  (13,  14).  To  determine  if the  LDV-infected AF 
might inhibit trapping via the T cell, we studied its effect on T-cell responsive- 
ness in vitro. 
Stimulation by the mitogens, Con A, and PHA was used as our assay ofT-cell 
reactivity.  Table III  shows the  data  from experiments  of PHA-P and  Con A 
stimulation of unfractionated LN cells and T cell-enriched LN cells. With both 
mitogens and with both populations of cells, the stimulation with LDV-infected 
AF in the culture medium was not significantly different from the stimulation 
with NMS in the culture medium. 
Neither viability nor in vitro reactivity of T cells to mitogens was influenced 
by the  presence  of LDV.  Thus,  LDV  does not  appear  to  inhibit  lymphocyte 
trapping by directly interfering with T-cell function. 
Discussion 
We extended the observation (2) that cell-free fluid from two ascitic tumors 
could inhibit lymphocyte trapping to three additional ascitic tumors in C3H-Bi 
mice  (3).  The  results  we report  here  in BALB/c mice  support  these  previous 
observations. 
Our results  implicate  LDV as the  trapping  inhibitory component in tumor 
AF: (a) the dose response endpoint for trapping inhibition by tumor AF corre- 
lates with the endpoint for LDV infectivity, and (b) elimination of infective LDV 
by ether-fractionation,  UV inactivation,  and  rat-passage  of the  ascitic tumor 
eliminates the capacity of the AF to inhibit lymphocyte trapping. To exclude the 
possibility  that  a  tumor-induced  trapping  inhibitory  factor  exists  which  is 
inactivated  by treatments  used  to  eliminate  LDV,  an  effective  neutralizing 
antibody is required. Total antibody neutralization of LDV is very difficult (15), 
and the presence of a  few residual  infectious units in an antibody-neutralized 
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LDV is frequently found in transplanted tumors (4, 5). This virus has not been 
found to replicate in tumor cells or to be oncogenic (16,  17), but is a  passenger 
virus transmitted  with tumor cells and oncogenic virus pools (10). 
LDV is difficult to characterize  by standard  methods.  Although  most of the 
virus is recovered in the pellet,  LDV has a  nonsedimentable infectious compo- 
nent after centrifugation at 105,000 g  for 4 h  (18).  The virus can have residual 
infectivity after 60°C incubation for 40 min (10). G-200 gel filtration of this virus 
has not been completely successful due to a minor fraction which tails from the 
major excluded fraction (10). Any residual virus in a fraction after a characteriza- 
tion step may cause misleading results.  We have shown that the few infectious 
units  in  a  5  x  10  -s  dilution  of AF  were  capable  of significantly  inhibiting 
trapping.  This is probably explained by the extremely rapid replication time of 
LDV, estimated at 30 min in vivo (10).  Because of these properties,  LDV may 
evade recognition and cause ambiguous results in procedures used to character- 
ize immunosuppressive components in tumor fluids. 
LDV has been thought to be a benign virus in that it does not affect mouse life 
span nor cause overt disease.  However, LDV does have effects on the immune 
system (6-8), and our results demonstrate that acute infection with LDV affects 
the  localization  of circulating  lymphocytes.  A  possible  mechanism  of LDV- 
induced  alteration  of lymphocyte circulation  is that  LDV  itself may  elicit  a 
trapping response in all the LNs. Smith and Morris have reported that viruses 
can elicit lymphocyte trapping (19). However, the profound changes observed in 
the histology of LNs early after LDV infection (6) do not support the existence of 
a  systemic lymphocyte trap.  In the first 48 h  after viral  infection a  depletion, 
rather  than  an  increase  in  number,  of lymphocytes  occurs  in  the  thymus- 
dependent areas of the spleen and the paracortical regions of LNs. This may be 
caused by a  cytotoxic degeneration of T cells and their phagocytosis by macro- 
phages (6). 
The depletion of cells in T-dependent areas may account for the alteration in 
lymphocyte localization  after  LDV inoculation.  The  increased  recovery of la- 
beled donor cells in peripheral LNs may be due to a greater sink for lymphocytes 
in the depleted areas and to continued cytotoxicity of incoming T lymphocytes in 
these regions.  The phagocytosis of degenerating labeled cells by macrophages 
may localize the label in the lymphatic organ. 
How does  LDV inhibit  SRBC-elicited  lymphocyte trapping?  Since  in  vitro 
treatment  of donor  cells  with  LDV-infected  AF did  not  significantly  inhibit 
trapping,  we believe LDV does not inhibit trapping by altering the circulating 
cells so that they cannot be trapped. 
LDV may inhibit trapping by affecting the induction of the lymphocyte trap. 
Although most evidence suggests that the macrophage is the cell that induces 
the trap (13, 20), some evidence suggests that the T cell may be an auxiliary cell 
to the macrophage (14). The evidence does not clearly implicate the macrophage 
or the T cell as the site of LDV inhibition of trapping. The following observations 
support the hypothesis that  LDV inhibits trapping  via the macrophage.  LDV 
appears to replicate exclusively in the macrophage (6),  and the first 48 h  after 
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tissue  (6).  Carbon clearance  by the  RES  is impaired  the  first few days after 
infection and returns to normal  after a week (7).  Correspondingly,  our results 
demonstrate that trapping is inhibited 2 days after LDV infection but not at 10 
days after infection. 
Although LDV has not been found to replicate in lymphocytes (6),  and LDV 
does not appear to affect T-cell viability nor reactivity to mitogens in vitro, the 
virus  may  indirectly  inhibit  trapping  via  the  T  cell.  In  vivo,  LDV infection 
results  in  a  transient  T-cell  depletion  possibly caused  by a  cytotoxic  factor 
released  by  LDV-infected  macrophages  (6).  If the  T  cell  is  involved  in  the 
induction of the trap,  the temporary loss of a  T-cell population in an antigen- 
draining  LN could explain how trapping is inhibited. 
Trapping inhibition by LDV may be partially or totally due to the changes in 
systemic  localization  of injected  lymphocytes.  The  increased  localization  of 
labeled cells in all LNs during an acute LDV infection may draw lymphocytes 
out of the  circulating  pool  available  for being trapped  in  the  SRBC-draining 
LNs. 
If trapping potentiates immune responses, LDV, which diminishes trapping, 
might  be expected to be immunosuppressive.  LDV prolongs  the  retention  of 
allogeneic  skin  grafts  (9),  potentiates  the  growth  of tumors  (21,  22),  and  in- 
creases or decreases antibody responses depending upon the time of LDV inocula- 
tion (8).  Several immunosuppressive properties of uncharacterized  fractions of 
tumors or tumor AFs (2, 23-26) could be due to LDV. 
LDV has a limited host range: the mouse. It may serve as a model for viruses 
in man which appear relatively benign, but may have the insidious capacity to 
alter the immunological capacity of the host. 
Summary 
Cell-free  fluid  from  several  ascites  promoting  tumors  inhibits  lymphocyte 
trapping.  Lactic  dehydrogenase  virus  (LDV),  a  common  passenger  virus  in 
many mouse tumors, was found to be a trapping inhibitory component in these 
fluids. Procedures used to eliminate infective LDV, such as dilution, passage of 
the  tumor  through  irradiated  rats,  ether  fractionation,  and  ultraviolet  (UV) 
irradiation  abolished the trapping inhibitory capacity of the fluids. LDV, disso- 
ciated from tumors,  was inhibitory.  Lymph nodes in mice with acute,  but not 
chronic,  LDV infections were inhibited from trapping.  LDV does not appear to 
inhibit  the  capacity  of circulating  cells  to  be  trapped,  and  as  measured  by 
mitogen responsiveness,  the virus does not directly interfere with T-cell func- 
tion.  LDV may inhibit  trapping  by indirectly  affecting the  T  cell  or directly 
affecting the macrophage in which it replicates.  The known characteristics  of 
LDV infection may explain a number of reported immunosuppressive attributes 
of tumor-associated ascitic fluids. 
The helpful  suggestions from Spencer Hiraki and the technical assistance  of  Doreen Hewgill are 
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